A Phase 2 Study of Datopotamab Deruxtecan Alone or With Other Anti-Cancer Drugs in People Endometrial, Ovarian, and Urothelial Cancers


Full Title

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours (TROPION-Pan Tumor 03)


Researchers want to see how well datopotamab deruxtecan (Dato-DXd) works alone and with other drugs against cancer. The people in this study have endometrial, ovarian, or urothelial cancer that has metastasized (spread).

If you join this study, you will get Dato-DXd alone or with either volrustomig (MEDI5752) or rilvegostomig (AZD2936). All of these medications are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have metastatic endometrial, ovarian, or urothelial cancer.
  • Have recovered from the serious side effects of previous treatments before getting the study therapy.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Vicky Makker’s office at 646-888-4224.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID